366 related articles for article (PubMed ID: 18650261)
1. A GSK-3/TSC2/mTOR pathway regulates glucose uptake and GLUT1 glucose transporter expression.
Buller CL; Loberg RD; Fan MH; Zhu Q; Park JL; Vesely E; Inoki K; Guan KL; Brosius FC
Am J Physiol Cell Physiol; 2008 Sep; 295(3):C836-43. PubMed ID: 18650261
[TBL] [Abstract][Full Text] [Related]
2. Enhanced expression of glucose transporter-1 in vascular smooth muscle cells via the Akt/tuberous sclerosis complex subunit 2 (TSC2)/mammalian target of rapamycin (mTOR)/ribosomal S6 protein kinase (S6K) pathway in experimental renal failure.
Lin CY; Hsu SC; Lee HS; Lin SH; Tsai CS; Huang SM; Shih CC; Hsu YJ
J Vasc Surg; 2013 Feb; 57(2):475-85. PubMed ID: 23265586
[TBL] [Abstract][Full Text] [Related]
3. GLUT1 enhances mTOR activity independently of TSC2 and AMPK.
Buller CL; Heilig CW; Brosius FC
Am J Physiol Renal Physiol; 2011 Sep; 301(3):F588-96. PubMed ID: 21613414
[TBL] [Abstract][Full Text] [Related]
4. GSK-3β at the crossroads in the signalling of heart preconditioning: implication of mTOR and Wnt pathways.
Vigneron F; Dos Santos P; Lemoine S; Bonnet M; Tariosse L; Couffinhal T; Duplaà C; Jaspard-Vinassa B
Cardiovasc Res; 2011 Apr; 90(1):49-56. PubMed ID: 21233250
[TBL] [Abstract][Full Text] [Related]
5. mTORC1 hyperactivity inhibits serum deprivation-induced apoptosis via increased hexokinase II and GLUT1 expression, sustained Mcl-1 expression, and glycogen synthase kinase 3beta inhibition.
Bhaskar PT; Nogueira V; Patra KC; Jeon SM; Park Y; Robey RB; Hay N
Mol Cell Biol; 2009 Sep; 29(18):5136-47. PubMed ID: 19620286
[TBL] [Abstract][Full Text] [Related]
6. Cytokine stimulation promotes glucose uptake via phosphatidylinositol-3 kinase/Akt regulation of Glut1 activity and trafficking.
Wieman HL; Wofford JA; Rathmell JC
Mol Biol Cell; 2007 Apr; 18(4):1437-46. PubMed ID: 17301289
[TBL] [Abstract][Full Text] [Related]
7. Interferon beta augments tuberous sclerosis complex 2 (TSC2)-dependent inhibition of TSC2-null ELT3 and human lymphangioleiomyomatosis-derived cell proliferation.
Goncharova EA; Goncharov DA; Chisolm A; Spaits MS; Lim PN; Cesarone G; Khavin I; Tliba O; Amrani Y; Panettieri RA; Krymskaya VP
Mol Pharmacol; 2008 Mar; 73(3):778-88. PubMed ID: 18094073
[TBL] [Abstract][Full Text] [Related]
8. Loss of tuberous sclerosis complex-2 function and activation of mammalian target of rapamycin signaling in endometrial carcinoma.
Lu KH; Wu W; Dave B; Slomovitz BM; Burke TW; Munsell MF; Broaddus RR; Walker CL
Clin Cancer Res; 2008 May; 14(9):2543-50. PubMed ID: 18451215
[TBL] [Abstract][Full Text] [Related]
9. Akt substrate TBC1D1 regulates GLUT1 expression through the mTOR pathway in 3T3-L1 adipocytes.
Zhou QL; Jiang ZY; Holik J; Chawla A; Hagan GN; Leszyk J; Czech MP
Biochem J; 2008 May; 411(3):647-55. PubMed ID: 18215134
[TBL] [Abstract][Full Text] [Related]
10. TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth.
Inoki K; Ouyang H; Zhu T; Lindvall C; Wang Y; Zhang X; Yang Q; Bennett C; Harada Y; Stankunas K; Wang CY; He X; MacDougald OA; You M; Williams BO; Guan KL
Cell; 2006 Sep; 126(5):955-68. PubMed ID: 16959574
[TBL] [Abstract][Full Text] [Related]
11. The tuberous sclerosis protein TSC2 is not required for the regulation of the mammalian target of rapamycin by amino acids and certain cellular stresses.
Smith EM; Finn SG; Tee AR; Browne GJ; Proud CG
J Biol Chem; 2005 May; 280(19):18717-27. PubMed ID: 15772076
[TBL] [Abstract][Full Text] [Related]
12. Activation of the mammalian target of rapamycin pathway acutely inhibits insulin signaling to Akt and glucose transport in 3T3-L1 and human adipocytes.
Tremblay F; Gagnon A; Veilleux A; Sorisky A; Marette A
Endocrinology; 2005 Mar; 146(3):1328-37. PubMed ID: 15576463
[TBL] [Abstract][Full Text] [Related]
13. Akt activates the mammalian target of rapamycin by regulating cellular ATP level and AMPK activity.
Hahn-Windgassen A; Nogueira V; Chen CC; Skeen JE; Sonenberg N; Hay N
J Biol Chem; 2005 Sep; 280(37):32081-9. PubMed ID: 16027121
[TBL] [Abstract][Full Text] [Related]
14. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling.
Inoki K; Li Y; Xu T; Guan KL
Genes Dev; 2003 Aug; 17(15):1829-34. PubMed ID: 12869586
[TBL] [Abstract][Full Text] [Related]
15. Homologous posttranscriptional regulation of insulin-like growth factor-I receptor level via glycogen synthase kinase-3beta and mammalian target of rapamycin in adrenal chromaffin cells: effect on tau phosphorylation.
Nemoto T; Satoh S; Maruta T; Kanai T; Yoshikawa N; Miyazaki S; Yanagita T; Wada A
Neuropharmacology; 2010 Jun; 58(7):1097-108. PubMed ID: 20144629
[TBL] [Abstract][Full Text] [Related]
16. The tuberous sclerosis complex regulates trafficking of glucose transporters and glucose uptake.
Jiang X; Kenerson H; Aicher L; Miyaoka R; Eary J; Bissler J; Yeung RS
Am J Pathol; 2008 Jun; 172(6):1748-56. PubMed ID: 18511518
[TBL] [Abstract][Full Text] [Related]
17. Insulin like growth factor-1-induced phosphorylation and altered distribution of tuberous sclerosis complex (TSC)1/TSC2 in C2C12 myotubes.
Miyazaki M; McCarthy JJ; Esser KA
FEBS J; 2010 May; 277(9):2180-91. PubMed ID: 20412061
[TBL] [Abstract][Full Text] [Related]
18. Association of focal adhesion kinase with tuberous sclerosis complex 2 in the regulation of s6 kinase activation and cell growth.
Gan B; Yoo Y; Guan JL
J Biol Chem; 2006 Dec; 281(49):37321-9. PubMed ID: 17043358
[TBL] [Abstract][Full Text] [Related]
19. Tuberous sclerosis-2 (TSC2) regulates the stability of death-associated protein kinase-1 (DAPK) through a lysosome-dependent degradation pathway.
Lin Y; Henderson P; Pettersson S; Satsangi J; Hupp T; Stevens C
FEBS J; 2011 Jan; 278(2):354-70. PubMed ID: 21134130
[TBL] [Abstract][Full Text] [Related]
20. Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML.
Zeng Z; Sarbassov dos D; Samudio IJ; Yee KW; Munsell MF; Ellen Jackson C; Giles FJ; Sabatini DM; Andreeff M; Konopleva M
Blood; 2007 Apr; 109(8):3509-12. PubMed ID: 17179228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
